Stocks opened lower in Tuesday's session on concerns over higher oil prices and after Monday's earnings report from Oracle that showed revenue came in weaker than expected.
Share:
More In Business
Was There a Palace Coup at the Magic Kingdom? Inside the Bob Iger, Bob Chapek Shake-up
James Stewart joins Cheddar to discuss his New York Times article on what really went on behind-the-scenes at Disney when Bob Iger took back his spot as CEO.
United Arab Emirates: Dubai’s Tourist Surge Hits 9.31M with D33 Goals
Dubai welcomed 9.31 million international tourists this year, a 9% increase. The 'D33' Agenda aims to double GDP by 2033 through innovative projects.
Regional Bank Boom: How Citizens Financial Is Crushing the S&P 500
Citizens Financial Group outpaced the S&P 500 with a 20.1% gain in 3 months, 25.7% YTD, and 51.3% in a year.
What Happens In Vegas! Sin City Debuts New Social Media Savvy Slogan
Steve Hill, CEO & President of Las Vegas Convention and Visitors Authority, talks all things Sin City including transportation news, nightlife and the Sphere!
FICO Utilizes AI To Enhance Business Decision-Making
AI is revolutionizing credit scoring by analyzing diverse data sources, enhancing accuracy & financial inclusion for those lacking traditional credit histories.
The Future of Mergers & Acquistions After Interest Rate Cuts
Founder & CEO at Align Business Advisory, Dena Jalbert, joins Cheddar to discuss the future of the M&A space and which sectors to watch out for. Watch!
Why A Champion Of The Four-Day Workweek Believes In It So Much
Working five days a week has long been the corporate cultural norm. But some companies are exploring the option of letting employees work four days a week.
Big Business This Week: It’s All Downhill From Here, Right?
After a two-year-long high, interest rates are coming back to earth. So what happens next? Plus: Boeing's woes, UAW may strike, and of course Elon's World.
How GNC Is Making Moves in the Age of Ozempic and Wegovy
GNC CEO, Michael Costello, joins Cheddar to discuss how the wellness business is evolving and what offerings they have similar to GLP-1 drugs. Watch!
